Several brokerages have updated their recommendations and price targets on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) in the last few weeks:

  • 11/20/2018 – Intercept Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $116.00 price target on the stock. According to Zacks, “Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC.  Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Solid growth in new patient enrollment in the third-quarter should lead to stronger sales in the fourth quarter. Moreover, the company is looking to expand the drug’s label in the promising NASH  and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Results from the REGENERATE trial are expected in the first half of 2019. However, we are concerned about the lack of other late-stage candidates in the company’s pipeline. Shares have outperformed the industry in the year so far.”
  • 11/19/2018 – Intercept Pharmaceuticals was upgraded by analysts at CIBC from a “market perform” rating to an “outperform” rating.
  • 11/19/2018 – Intercept Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $140.00 price target on the stock.
  • 11/19/2018 – Intercept Pharmaceuticals was upgraded by analysts at UBS Group AG from a “market perform” rating to an “outperform” rating.
  • 11/16/2018 – Intercept Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intercept’s third-quarter results were encouraging, with the company beating on both top and bottom-lines. Sales had earlier taken a hit due to the safety issues regarding Ocaliva. Nevertheless, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Solid growth in new patient enrollment should lead to stronger sales in the fourth quarter. Moreover, the company is looking to expand the drug’s label in the promising NASH space. Results from the REGENERATE trial are expected in the first half of 2018 for the NASH indication. However, we are also concerned about the lack of other late-stage candidates in the company’s pipeline. Shares have outperformed the industry in the year so far.”
  • 11/13/2018 – Intercept Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $113.00 price target on the stock. According to Zacks, “Intercept’s third-quarter results were encouraging, with the company beating on both top and bottom-lines.  Sales had earlier taken a hit due to the safety issues regarding Ocaliva. Nevertheless, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Solid growth in new patient enrollment should lead to stronger sales in the fourth quarter. Moreover, the company is looking to expand the drug’s label in the promising NASH space. However, we are also concerned about the lack of other late-stage candidates in the company’s pipeline. Shares have outperformed the industry in the year so far.”
  • 11/12/2018 – Intercept Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/6/2018 – Intercept Pharmaceuticals was given a new $220.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 10/31/2018 – Intercept Pharmaceuticals was given a new $100.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “hold” rating on the stock.
  • 10/31/2018 – Intercept Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 10/19/2018 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/11/2018 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/8/2018 – Intercept Pharmaceuticals was given a new $100.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “hold” rating on the stock.
  • 10/8/2018 – Intercept Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 10/2/2018 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/2/2018 – Intercept Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 10/2/2018 – Intercept Pharmaceuticals was downgraded by analysts at Raymond James from a “strong-buy” rating to an “outperform” rating. They now have a $141.00 price target on the stock, up previously from $126.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 10/1/2018 – Intercept Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
  • 9/22/2018 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

ICPT traded up $2.98 during trading hours on Wednesday, reaching $109.73. 304,783 shares of the company’s stock traded hands, compared to its average volume of 668,091. Intercept Pharmaceuticals Inc has a 52-week low of $51.05 and a 52-week high of $133.74. The company has a quick ratio of 5.98, a current ratio of 5.98 and a debt-to-equity ratio of 3.83. The stock has a market cap of $3.08 billion, a P/E ratio of -7.63 and a beta of -1.08.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.65) by $0.47. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The company had revenue of $47.00 million during the quarter, compared to analysts’ expectations of $48.24 million. During the same quarter in the previous year, the business earned ($2.89) EPS. Intercept Pharmaceuticals’s revenue was up 13.8% compared to the same quarter last year. Equities analysts anticipate that Intercept Pharmaceuticals Inc will post -10 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, insider David Shapiro sold 4,917 shares of the company’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $111.43, for a total value of $547,901.31. Following the completion of the sale, the insider now directly owns 42,196 shares in the company, valued at approximately $4,701,900.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Mark Pruzanski sold 50,000 shares of the company’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $101.07, for a total value of $5,053,500.00. Following the completion of the sale, the chief executive officer now owns 589,199 shares of the company’s stock, valued at $59,550,342.93. The disclosure for this sale can be found here. Insiders sold a total of 61,101 shares of company stock valued at $6,230,628 over the last quarter. Company insiders own 4.90% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its position in shares of Intercept Pharmaceuticals by 30.8% in the 3rd quarter. Legal & General Group Plc now owns 8,849 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 2,086 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Intercept Pharmaceuticals by 3.0% in the 3rd quarter. Teachers Advisors LLC now owns 43,018 shares of the biopharmaceutical company’s stock worth $5,436,000 after acquiring an additional 1,254 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Intercept Pharmaceuticals in the 3rd quarter worth $2,764,000. Macquarie Group Ltd. raised its position in shares of Intercept Pharmaceuticals by 158.8% in the 3rd quarter. Macquarie Group Ltd. now owns 35,561 shares of the biopharmaceutical company’s stock worth $4,493,000 after acquiring an additional 21,819 shares in the last quarter. Finally, Advisors Asset Management Inc. bought a new position in shares of Intercept Pharmaceuticals in the 3rd quarter worth $846,000. Institutional investors and hedge funds own 63.20% of the company’s stock.

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Article: Swap

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.